Epitalon — Research, Dosing & Price Guide

Epitalon (Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural pineal gland peptide epithalamin, developed by Russian gerontologist Professor Vladimir Khavinson over three decades of research. It is the most extensively studied telomerase-activating peptide, shown to lengthen telomeres, restore melatonin production, and extend lifespan in multiple animal models. Epitalon occupies a unique position in anti-aging research as one of the few compounds with direct evidence of telomere elongation in human cell cultures.

Epitalon's primary anti-aging mechanism centers on activation of telomerase, the ribonucleoprotein enzyme responsible for maintaining telomere length at chromosome ends. Telomeres are repetitive TTAGGG nucleotide sequences that protect chromosomal DNA during cell division; with each replication cycle, telomeres shorten by 50–200 base pairs. When telomeres reach a critical minimum length (~5 kilobases), the cell enters replicative senescence — it stops dividing and begins secreting pro-inflammatory cytokines (the senescence-associated secretory phenotype, or SASP). Epitalon activates the hTERT gene, which encodes the catalytic subunit of human telomerase reverse transcriptase. By upregulating hTERT expression, Epitalon enables cells to add telomeric repeats back onto chromosome ends, effectively resetting the replicative clock. In vitro studies on human fetal fibroblasts and adult somatic cells have demonstrated that Epitalon treatment extends replicative capacity by 10–20 additional population doublings beyond the normal Hayflick limit. Beyond telomerase activation, Epitalon restores circadian melatonin secretion from the pineal gland. The pineal gland calcifies and loses function with age, reducing melatonin output — a key driver of age-related sleep disruption and antioxidant decline. Epitalon has been shown to restore nighttime melatonin peaks in elderly subjects to levels comparable to younger individuals. This is significant because melatonin is not just a sleep hormone; it is a potent free radical scavenger that protects mitochondrial DNA from oxidative damage. Epitalon also modulates the expression of genes involved in antioxidant defense (superoxide dismutase, glutathione peroxidase), apoptosis regulation, and immune function. It upregulates interferon-gamma production and normalizes T-lymphocyte subpopulations, contributing to immunosenescence reversal. The peptide also normalizes anterior pituitary hormone secretion, including growth hormone and gonadotropins, which decline with age.

• Khavinson and colleagues demonstrated that Epitalon increased telomerase activity by 2.4-fold in human fetal lung fibroblasts and extended their replicative lifespan by 10 additional doublings (Bulletin of Experimental Biology and Medicine, 2003)
• A 15-year longitudinal study in elderly patients receiving epithalamin (Epitalon's precursor) showed a 28% reduction in cardiovascular mortality compared to untreated controls (Neuroendocrinology Letters, 2003)
• Anisimov et al. (2001) published in Biogerontology showing Epitalon increased mean lifespan by 13.3% in female CBA mice and suppressed spontaneous tumor incidence
• Studies in aged rhesus monkeys demonstrated restoration of evening melatonin peaks to youthful levels after a 10-day Epitalon course (Experimental Gerontology, 2004)
• Khavinson published in the Bulletin of Experimental Biology and Medicine (2004) showing Epitalon reactivated telomerase in human somatic cells from donors aged 60–80 years
• A study on elderly night-shift workers showed Epitalon normalized disrupted cortisol rhythms and improved sleep quality scores by 40% (Advances in Gerontology, 2006)
• Research demonstrated Epitalon reduced lipid peroxidation products by 30% in aging rats, suggesting systemic antioxidant effects (Mechanisms of Ageing and Development, 2003)
• Peptide bioregulation studies by Khavinson showed Epitalon normalized chromatin structure in aged lymphocytes, reactivating previously silenced gene expression
• A study in elderly patients (Advances in Gerontology, 2002) showed Epitalon treatment improved immune markers including normalized CD4/CD8 T-cell ratios and increased natural killer cell activity
• Research in Drosophila melanogaster demonstrated Epitalon extended maximum lifespan by 16%, providing cross-species evidence for its longevity effects

• Standard protocol: 5–10 mg subcutaneous injection daily for 10–20 consecutive days, repeated every 4–6 months
• Khavinson clinical protocol: 10 mg IV or IM daily for 10 days, performed 2–3 times per year
• Conservative protocol: 5 mg subcutaneous injection daily for 10 days every 6 months
• Some practitioners use 1–3 mg daily for 20 days for a lower-dose, longer-duration approach
• Inject in the evening (before bed) to align with natural melatonin secretion patterns
• Intranasal formulation (na-epitalon): 1–3 sprays per nostril daily for 30 days
• No loading phase required — effects are cumulative across treatment courses
• Allow minimum 4 months between courses to assess telomere response

Known Side Effects

• Injection site reactions: mild redness, swelling, or itching (common, transient, resolves within 1 hour)
• Temporary flushing or warmth sensation immediately after injection, especially with higher doses
• Mild headache during first 2–3 days of treatment course, reported in <10% of users
• Increased dream vividness and deeper sleep (often considered a positive effect of restored melatonin)
• Rare: mild fatigue during the treatment course as circadian rhythms readjust
• No serious adverse events reported in over 30 years of clinical research in Russia

Safety Profile

Epitalon has an exceptionally well-documented safety profile spanning over three decades of clinical use in Russia. Professor Khavinson's research program included studies with over 15,000 participants, and no significant adverse events were attributed to the peptide. The 15-year elderly cohort study (St. Petersburg Institute of Bioregulation and Gerontology) demonstrated that long-term intermittent Epitalon use was associated with reduced mortality, not increased risk. Importantly, Epitalon activates telomerase transiently — it does not produce constitutive telomerase activation, which would carry theoretical oncogenic risk. The short treatment courses (10–20 days) followed by months-long breaks allow cells to benefit from telomere extension without sustained telomerase overexpression. There is no evidence of tumor promotion in any animal or human study. Contraindications are minimal: avoid during active cancer treatment (theoretical concern about telomerase in malignant cells), pregnancy, and breastfeeding. No drug interactions have been documented. Safe for long-term intermittent use.

Days 1–5: Most users notice improved sleep quality and faster sleep onset within the first few days, reflecting early melatonin restoration. Energy levels may fluctuate as circadian rhythms readjust. Days 5–10: Deeper, more restorative sleep becomes consistent. Many report improved morning alertness and reduced daytime fatigue. Some users note improved skin texture and appearance, likely related to enhanced nighttime growth hormone release. Weeks 2–8 post-course: The full anti-aging benefits unfold over weeks to months as telomerase activation extends telomeres during normal cell division cycles. Improved immune function, better stress resilience, and sustained sleep quality improvements are commonly reported. Subsequent courses (4–6 months later): Each treatment course builds on previous gains. Long-term users report sustained vitality improvements, better skin quality, improved cognitive clarity, and a general sense of biological age reversal. Telomere length measurements (if performed) may show stabilization or modest elongation over 1–2 years of intermittent treatment.

Prices sourced from peptides.gg marketplace. Prices may vary.